<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255047</url>
  </required_header>
  <id_info>
    <org_study_id>M5A10</org_study_id>
    <nct_id>NCT00255047</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response of Different Pediatric Combination Vaccines.</brief_title>
  <official_title>Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to corroborate that a schedule consisting of 3 doses of
      Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of
      Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3
      doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus
      vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations.</measure>
    <time_frame>30 Days post-dose 3 vaccination</time_frame>
    <description>Vaccine response was calculated as a pre-dose 1 titer ≤ Lower Limit of Quantitation (LLOQ) and post-dose 3 titer &gt; LLOQ; or a pre-dose 1 titer &gt; LLOQ and post-dose 3 titer ≥ pre-dose 1 titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Four-fold Rise in Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations (Seroconversion)</measure>
    <time_frame>30 Days post-dose 3 vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antibodies to Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Antigens Post-dose 3 Vaccinations.</measure>
    <time_frame>30 Days post-dose 3 vaccination.</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reactions Post-vaccination 3</measure>
    <time_frame>7 days post-vaccination 3</time_frame>
    <description>Solicited injection site reactions: Tenderness, Redness, and Swelling. Solicited systemic reactions: Fever (body temperature), Vomiting, Abnormal crying, Lethargy, Appetite decreased, Irritability, and Rash.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2167</enrollment>
  <condition>Diphtheria</condition>
  <condition>Polio</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Study Group 1: DAPTACEL®, ActHIB®, and IPOL®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2: Pentacel®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3: DTaP-IPV and ActHIB®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4: Pentacel®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAPTACEL®. (DTaP), IPOL®., and ActHIB®.</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 1: DAPTACEL®, ActHIB®, and IPOL®</arm_group_label>
    <other_name>DAPTACEL®</other_name>
    <other_name>IPOL®</other_name>
    <other_name>ActHIB®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel®: DTaP-IPV/Hib combined</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 2: Pentacel®</arm_group_label>
    <other_name>Pentacel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV and ActHIB®</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 3: DTaP-IPV and ActHIB®</arm_group_label>
    <other_name>ActHIB®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel®: DTaP-IPV/Hib combined</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 4: Pentacel®</arm_group_label>
    <other_name>Pentacel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 42 days and ≤ 89 days on the day of inclusion

          -  Born at full term of pregnancy (≥ 36 weeks)

          -  Informed consent form signed by the parent(s) or other legally authorized
             representative(s) before the 1st study related procedure

          -  Vaccination with a hepatitis B vaccine at least 30 days before inclusion

          -  Able to attend all scheduled visits and to comply with all trial procedures(i.e.,
             access to a phone)

          -  Provide blood sample prior to Dose 1

          -  Parent or legal representative willing to take rectal temperatures after each
             vaccination.

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the (first)trial
             vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Personal or immediate family history of congenital or acquired immunodeficiency,
             immunosuppressive therapy such as long-term systemic corticosteroids therapy

          -  Known or suspected systemic hypersensitivity to any of the vaccine components or
             history of a life-threatening reaction to a vaccine containing the same substances as
             the trial vaccine(s)

          -  Chronic illness that could interfere with trial conduct or completion

          -  Received blood or blood-derived products since birth

          -  Any vaccination in the 2 weeks preceding the first trial vaccination or planned in the
             4 weeks after any trial vaccination. Flu vaccine could be administered only 2 weeks
             after any trial vaccination

          -  Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis-
             (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)-conjugate,
             poliovirus, or pneumococcal conjugate vaccines

          -  Coagulation disorder contraindicating intramuscular (IM) vaccination

          -  Clinically significant findings on review of systems (determined by investigator or
             sub-investigator to be sufficient for exclusion)

          -  Developmental delay or neurological disorder

          -  Any condition which, in the opinion of the investigator, would interfere with the
             evaluation of the vaccine or pose a health risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2005</study_first_posted>
  <results_first_submitted>September 14, 2010</results_first_submitted>
  <results_first_submitted_qc>October 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2010</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pertussis</keyword>
  <keyword>Whooping cough</keyword>
  <keyword>Filamentous Haemagglutinin</keyword>
  <keyword>Fimbriae Types 2 and 3;</keyword>
  <keyword>Pertactin</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Poliovirus Types 1, 2, and 3.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 10 November 2005 through 21 September 2006 in 38 Clinics in the Untied States.</recruitment_details>
      <pre_assignment_details>A total of 2167 participants that met the inclusion and exclusion criteria were enrolled and vaccinated. Data on Stage I, up to the 3rd dose are presented.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="P2">
          <title>Study Group 2: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
        <group group_id="P3">
          <title>Study Group 3: DTaP-IPV and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="P4">
          <title>Study Group 4: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="538"/>
                <participants group_id="P2" count="535"/>
                <participants group_id="P3" count="546"/>
                <participants group_id="P4" count="548"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="490"/>
                <participants group_id="P2" count="487"/>
                <participants group_id="P3" count="496"/>
                <participants group_id="P4" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Events</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="B2">
          <title>Study Group 2: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
        <group group_id="B3">
          <title>Study Group 3: DTaP-IPV and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Study Group 4: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="538"/>
            <count group_id="B2" value="535"/>
            <count group_id="B3" value="546"/>
            <count group_id="B4" value="548"/>
            <count group_id="B5" value="2167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="535"/>
                    <measurement group_id="B3" value="546"/>
                    <measurement group_id="B4" value="548"/>
                    <measurement group_id="B5" value="2167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="0.27"/>
                    <measurement group_id="B2" value="2.1" spread="0.27"/>
                    <measurement group_id="B3" value="2.2" spread="0.27"/>
                    <measurement group_id="B4" value="2.1" spread="0.28"/>
                    <measurement group_id="B5" value="2.1" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="274"/>
                    <measurement group_id="B5" value="1016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="297"/>
                    <measurement group_id="B4" value="274"/>
                    <measurement group_id="B5" value="1151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="535"/>
                    <measurement group_id="B3" value="546"/>
                    <measurement group_id="B4" value="548"/>
                    <measurement group_id="B5" value="2167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations.</title>
        <description>Vaccine response was calculated as a pre-dose 1 titer ≤ Lower Limit of Quantitation (LLOQ) and post-dose 3 titer &gt; LLOQ; or a pre-dose 1 titer &gt; LLOQ and post-dose 3 titer ≥ pre-dose 1 titer.</description>
        <time_frame>30 Days post-dose 3 vaccination</time_frame>
        <population>The vaccine response to pertussis antigens were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3: DTaP-IPV and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations.</title>
          <description>Vaccine response was calculated as a pre-dose 1 titer ≤ Lower Limit of Quantitation (LLOQ) and post-dose 3 titer &gt; LLOQ; or a pre-dose 1 titer &gt; LLOQ and post-dose 3 titer ≥ pre-dose 1 titer.</description>
          <population>The vaccine response to pertussis antigens were determined in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis Toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 (FIM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Four-fold Rise in Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations (Seroconversion)</title>
        <time_frame>30 Days post-dose 3 vaccination</time_frame>
        <population>Four-fold rise titers (seroconversion) were evaluated in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3: DTaP-IPV and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Four-fold Rise in Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations (Seroconversion)</title>
          <population>Four-fold rise titers (seroconversion) were evaluated in the per-protocol population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="411"/>
                <count group_id="O4" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis Toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (PRN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 (FIM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reactions Post-vaccination 3</title>
        <description>Solicited injection site reactions: Tenderness, Redness, and Swelling. Solicited systemic reactions: Fever (body temperature), Vomiting, Abnormal crying, Lethargy, Appetite decreased, Irritability, and Rash.</description>
        <time_frame>7 days post-vaccination 3</time_frame>
        <population>Solicited injection site and systemic reactions were evaluated in the intend-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3: DTaP-IPV and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reactions Post-vaccination 3</title>
          <description>Solicited injection site reactions: Tenderness, Redness, and Swelling. Solicited systemic reactions: Fever (body temperature), Vomiting, Abnormal crying, Lethargy, Appetite decreased, Irritability, and Rash.</description>
          <population>Solicited injection site and systemic reactions were evaluated in the intend-to-treat (ITT) population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="535"/>
                <count group_id="O3" value="546"/>
                <count group_id="O4" value="548"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="164"/>
                    <measurement group_id="O4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema Any dose (&gt;50 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling Any dose (&gt;50 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="150"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Tenderness (cries when inj. limb is moved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="328"/>
                    <measurement group_id="O4" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt; 39.5 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Vomitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomitting (≥3 episodes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Anormal crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Abnormal crying (Inconsolable &gt; 3 hrs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Lethargy (disabling)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Appetite decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite decreased (skips ≥ 2 meals)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="254"/>
                    <measurement group_id="O4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (continuously for &gt;3 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Antibodies to Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Antigens Post-dose 3 Vaccinations.</title>
        <time_frame>30 Days post-dose 3 vaccination.</time_frame>
        <population>Geometric mean titers were evaluated in the per-protocol immunogenicity population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3: DTaP-IPV and ActHIB®</title>
            <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4: Pentacel®</title>
            <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Antibodies to Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Antigens Post-dose 3 Vaccinations.</title>
          <population>Geometric mean titers were evaluated in the per-protocol immunogenicity population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="414"/>
                <count group_id="O4" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis Toxoid (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.48" lower_limit="62.54" upper_limit="70.67"/>
                    <measurement group_id="O2" value="96.8" lower_limit="91.4" upper_limit="102.4"/>
                    <measurement group_id="O3" value="116.86" lower_limit="110.60" upper_limit="123.47"/>
                    <measurement group_id="O4" value="97.8" lower_limit="92.5" upper_limit="103.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.51" lower_limit="20.94" upper_limit="24.20"/>
                    <measurement group_id="O2" value="53.0" lower_limit="49.7" upper_limit="56.6"/>
                    <measurement group_id="O3" value="56.88" lower_limit="53.26" upper_limit="60.74"/>
                    <measurement group_id="O4" value="54.1" lower_limit="50.9" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.63" lower_limit="30.92" upper_limit="36.58"/>
                    <measurement group_id="O2" value="32.5" lower_limit="29.5" upper_limit="35.9"/>
                    <measurement group_id="O3" value="44.70" lower_limit="40.95" upper_limit="48.80"/>
                    <measurement group_id="O4" value="32.5" lower_limit="29.5" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.66" lower_limit="166.62" upper_limit="198.06"/>
                    <measurement group_id="O2" value="188.5" lower_limit="173.9" upper_limit="204.3"/>
                    <measurement group_id="O3" value="273.10" lower_limit="254.83" upper_limit="292.67"/>
                    <measurement group_id="O4" value="199.0" lower_limit="184.3" upper_limit="214.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polyribosylribitol Phosphate-Tetanus Toxoid; μg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="2.01" upper_limit="2.81"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.2" upper_limit="2.9"/>
                    <measurement group_id="O3" value="3.76" lower_limit="3.25" upper_limit="4.34"/>
                    <measurement group_id="O4" value="2.5" lower_limit="2.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria (IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.29" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.37" lower_limit="0.33" upper_limit="0.41"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus toxoid (IU/mL, ≥ 0.01)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.91" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="0.8"/>
                    <measurement group_id="O3" value="1.09" lower_limit="1.02" upper_limit="1.17"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.7" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Types 1 (≥ 1:8 dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="719.83" lower_limit="645.73" upper_limit="802.42"/>
                    <measurement group_id="O2" value="397.7" lower_limit="342.8" upper_limit="461.5"/>
                    <measurement group_id="O3" value="776.44" lower_limit="676.85" upper_limit="890.68"/>
                    <measurement group_id="O4" value="468.3" lower_limit="406.3" upper_limit="539.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Types 2 (≥ 1:8 dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734.50" lower_limit="668.28" upper_limit="807.28"/>
                    <measurement group_id="O2" value="699.5" lower_limit="623.6" upper_limit="784.6"/>
                    <measurement group_id="O3" value="1203.20" lower_limit="1082.31" upper_limit="1337.60"/>
                    <measurement group_id="O4" value="812.5" lower_limit="727.3" upper_limit="907.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Types 3 (≥ 1:8 dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="916.90" lower_limit="829.15" upper_limit="1013.92"/>
                    <measurement group_id="O2" value="666.6" lower_limit="584.7" upper_limit="760.0"/>
                    <measurement group_id="O3" value="1115.00" lower_limit="976.11" upper_limit="1273.65"/>
                    <measurement group_id="O4" value="819.9" lower_limit="715.8" upper_limit="939.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected for 4 months post-vaccination 1 (Stage I)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group 1: DAPTACEL®, IPOL®, and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DAPTACEL®, IPOL®, and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="E2">
          <title>Study Group 2: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
        <group group_id="E3">
          <title>Study Group 3: DTaP-IPV and ActHIB®</title>
          <description>Participants received 3 doses (0.5 mL each) of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively.</description>
        </group>
        <group group_id="E4">
          <title>Study Group 4: Pentacel®</title>
          <description>Participants received 3 doses (0.5 mL each) of Pentacel® at Months 2, 4, and 6 respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="535"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="546"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital aortic anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Congenital ventricular septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hepatic arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Upper extremity mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="538"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="535"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="546"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Kawasaki´s disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="535"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>General nutrition disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="546"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Hypotonic-hyporesponsive episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="546"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="399" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="535"/>
                <counts group_id="E3" subjects_affected="421" subjects_at_risk="546"/>
                <counts group_id="E4" subjects_affected="414" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="44" subjects_affected="39" subjects_at_risk="538"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="535"/>
                <counts group_id="E3" events="43" subjects_affected="41" subjects_at_risk="546"/>
                <counts group_id="E4" events="43" subjects_affected="41" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="44" subjects_affected="35" subjects_at_risk="538"/>
                <counts group_id="E2" events="43" subjects_affected="33" subjects_at_risk="535"/>
                <counts group_id="E3" events="40" subjects_affected="30" subjects_at_risk="546"/>
                <counts group_id="E4" events="48" subjects_affected="34" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="169" subjects_affected="128" subjects_at_risk="532"/>
                <counts group_id="E2" events="153" subjects_affected="119" subjects_at_risk="533"/>
                <counts group_id="E3" events="174" subjects_affected="131" subjects_at_risk="538"/>
                <counts group_id="E4" events="150" subjects_affected="119" subjects_at_risk="543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="27" subjects_at_risk="538"/>
                <counts group_id="E2" events="34" subjects_affected="33" subjects_at_risk="535"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="546"/>
                <counts group_id="E4" events="27" subjects_affected="25" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="174" subjects_affected="90" subjects_at_risk="532"/>
                <counts group_id="E2" events="83" subjects_affected="65" subjects_at_risk="533"/>
                <counts group_id="E3" events="107" subjects_affected="64" subjects_at_risk="538"/>
                <counts group_id="E4" events="82" subjects_affected="66" subjects_at_risk="543"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="102" subjects_affected="49" subjects_at_risk="532"/>
                <counts group_id="E2" events="59" subjects_affected="50" subjects_at_risk="533"/>
                <counts group_id="E3" events="77" subjects_affected="43" subjects_at_risk="538"/>
                <counts group_id="E4" events="71" subjects_affected="49" subjects_at_risk="543"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1406" subjects_affected="342" subjects_at_risk="532"/>
                <counts group_id="E2" events="545" subjects_affected="310" subjects_at_risk="533"/>
                <counts group_id="E3" events="967" subjects_affected="301" subjects_at_risk="538"/>
                <counts group_id="E4" events="542" subjects_affected="310" subjects_at_risk="543"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="300" subjects_affected="219" subjects_at_risk="531"/>
                <counts group_id="E2" events="254" subjects_affected="199" subjects_at_risk="533"/>
                <counts group_id="E3" events="304" subjects_affected="221" subjects_at_risk="537"/>
                <counts group_id="E4" events="268" subjects_affected="208" subjects_at_risk="543"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="456" subjects_affected="271" subjects_at_risk="532"/>
                <counts group_id="E2" events="415" subjects_affected="275" subjects_at_risk="533"/>
                <counts group_id="E3" events="415" subjects_affected="262" subjects_at_risk="538"/>
                <counts group_id="E4" events="369" subjects_affected="239" subjects_at_risk="543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="538"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="535"/>
                <counts group_id="E3" events="30" subjects_affected="28" subjects_at_risk="546"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="86" subjects_affected="72" subjects_at_risk="538"/>
                <counts group_id="E2" events="117" subjects_affected="97" subjects_at_risk="535"/>
                <counts group_id="E3" events="109" subjects_affected="93" subjects_at_risk="546"/>
                <counts group_id="E4" events="94" subjects_affected="75" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="164" subjects_affected="143" subjects_at_risk="538"/>
                <counts group_id="E2" events="167" subjects_affected="141" subjects_at_risk="535"/>
                <counts group_id="E3" events="162" subjects_affected="134" subjects_at_risk="546"/>
                <counts group_id="E4" events="167" subjects_affected="141" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="538"/>
                <counts group_id="E2" events="32" subjects_affected="31" subjects_at_risk="535"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="546"/>
                <counts group_id="E4" events="23" subjects_affected="23" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="295" subjects_affected="214" subjects_at_risk="532"/>
                <counts group_id="E2" events="253" subjects_affected="191" subjects_at_risk="533"/>
                <counts group_id="E3" events="267" subjects_affected="192" subjects_at_risk="538"/>
                <counts group_id="E4" events="251" subjects_affected="174" subjects_at_risk="543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anbormal crying</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="495" subjects_affected="287" subjects_at_risk="532"/>
                <counts group_id="E2" events="446" subjects_affected="282" subjects_at_risk="533"/>
                <counts group_id="E3" events="452" subjects_affected="275" subjects_at_risk="539"/>
                <counts group_id="E4" events="442" subjects_affected="285" subjects_at_risk="543"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="820" subjects_affected="399" subjects_at_risk="532"/>
                <counts group_id="E2" events="795" subjects_affected="394" subjects_at_risk="533"/>
                <counts group_id="E3" events="820" subjects_affected="421" subjects_at_risk="539"/>
                <counts group_id="E4" events="800" subjects_affected="414" subjects_at_risk="543"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="42" subjects_affected="37" subjects_at_risk="538"/>
                <counts group_id="E2" events="54" subjects_affected="49" subjects_at_risk="535"/>
                <counts group_id="E3" events="51" subjects_affected="45" subjects_at_risk="546"/>
                <counts group_id="E4" events="47" subjects_affected="44" subjects_at_risk="548"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="59" subjects_affected="51" subjects_at_risk="538"/>
                <counts group_id="E2" events="57" subjects_affected="49" subjects_at_risk="535"/>
                <counts group_id="E3" events="59" subjects_affected="50" subjects_at_risk="546"/>
                <counts group_id="E4" events="46" subjects_affected="42" subjects_at_risk="548"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

